Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
RNA Frontie | Explore Silence Therapeutics's position in RNA therapeutics, focusing on cardiovascular and hematological disorders with promising clinical results |
Zerlasiran's Potential | Delve into Zerlasiran's market opportunity, with analysts anticipating 50-100%+ stock upside upon partnership announcement |
Divesiran Breakthrough | Learn about Divesiran's impact on Polycythemia Vera treatment, reducing phlebotomy needs and garnering significant partnership interest |
Financial Outlook | Analysts project $30M revenue for 2024-2025, with price targets ranging from $67 to $75, despite current trading near 52-week low of $4.82 |
Metrics to compare | SLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLNPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.0x | −2.6x | −0.5x | |
PEG Ratio | 0.04 | −0.09 | 0.00 | |
Price/Book | 2.5x | 2.7x | 2.6x | |
Price / LTM Sales | 8.8x | 9.7x | 3.3x | |
Upside (Analyst Target) | - | 266.1% | 43.4% | |
Fair Value Upside | Unlock | 14.6% | 7.1% | Unlock |